The collective findings emphasize the significance of the FOXA1-BMI1 interaction in regulating cisplatin sensitivity in NPC, suggesting that targeting this axis could be key to enhancing chemosensitivity and optimizing treatment efficacy. This evidence concerns the gene FOXA1 and nasopharyngeal carcinoma.